Botulinum Toxin Type A for Postoperative Scar Prevention: A Systematic Review and Meta-analysis
Aesthetic Surgery Journal · 22.09.2026
DOI: 10.1093/asj/sjag204 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Aesthetic Surgery Journal, online erschienen am 22.09.2026. Verfasst von Yi-Hsin Ho und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Taipei Veterans General Hospital, Taipei, Taiwan. Die Arbeit nennt 45 Literaturangaben. Gefördert von: Ministry of Health and Welfare, Taiwan, National Health Research Institutes, Taiwan, Ministry of Economic Affairs, Taiwan.
Abstract (Originalsprache)
Postoperative scars may impair quality of life. Prophylactic botulinum toxin type A (BoNT-A) may reduce scarring, but optimal timing, dose density, injection plane, and anatomic indications remain uncertain. This systematic review and meta-analysis evaluated prophylactic BoNT-A for postoperative scar prevention and examined effect modification by timing, dose density, and anatomic site; injection-plane practices were summarized descriptively. Four databases were searched through January 2026 for comparative trials of perioperative or postoperative BoNT-A administration. Random-effects meta-analysis used standardized mean differences (SMDs); subgroup analyses and meta-regression examined timing, dose density, and anatomic site. Seventeen studies (656 treatment sites; 456 participants) were included. BoNT-A improved clinician composite scores (SMD, −0.864; 95% CI, −1.137 to −0.591; low certainty), clinician VAS (SMD, −0.951; 95% CI, −1.468 to −0.434; very low certainty), and objective scar width (SMD, −0.924; 95% CI, −1.119 to −0.728; moderate certainty). Exploratory pooled analyses using the original study-level timing assignments suggested a larger effect with delayed injection (SMD, −1.240; moderate certainty) than with immediate injection (SMD, −0.559; low certainty). Timing and anatomic site jointly accounted for 81% of heterogeneity (P = .0008), with effects largest in chest and smallest in fine facial sites. Moderate-certainty evidence supports reduced objective scar width; clinician composite scales improved with low certainty. Pooled clinician-composite analyses suggested larger effects with delayed injection, although direct within-site timing studies have reported conflicting findings. Immediate-injection evidence and patient-reported outcomes remain uncertain, and cross-study dose escalation within 4 to 10 U/cm was not associated with additional benefit. Level of Evidence: 3 (Therapeutic) For image description, please refer to the figure legend and surrounding text.
Autor:innen und Institutionen
- Department of Dermatology, Taipei Veterans General Hospital, Taipei, Taiwan.
- Division of Urology, Department of Surgery, Taipei City Hospital Heping-Fuyou Branch, Taipei, Taiwan.
- Institute of Neuroscience, National Yang Ming Chiao Tung University, Taipei, Taiwan.
- Oral & Maxillofacial Surgery, Department of Stomatology, Taipei Veterans General Hospital, Taipei, Taiwan.
ORCID-Profile: Chih-Chiang Chen, Ching-Po Lin
Förderung
- Ministry of Health and Welfare, Taiwan
- National Health Research Institutes, Taiwan
- Ministry of Economic Affairs, Taiwan
- National Science and Technology Council, Taiwan
- Department of Health, Taipei City Government, Taiwan
Zitieren
APA
Ho, Y. H., Chang, T. W., Hsu, C. W., Ho, Y. Y., Chen, C. C., & Lin, C. P. (2026). Botulinum Toxin Type A for Postoperative Scar Prevention: A Systematic Review and Meta-analysis. Aesthetic Surgery Journal. https://doi.org/10.1093/asj/sjag204
Vancouver
Ho YH, Chang TW, Hsu CW, Ho YY, Chen CC, Lin CP. Botulinum Toxin Type A for Postoperative Scar Prevention: A Systematic Review and Meta-analysis. Aesthetic Surgery Journal. 2026. doi:10.1093/asj/sjag204
BibTeX
@article{Ho2026,
author = {Ho, Yi-Hsin and Chang, Te-Wei and Hsu, Chun-Wei and Ho, Yi-Yun and Chen, Chih-Chiang and Lin, Ching-Po},
title = {Botulinum Toxin Type A for Postoperative Scar Prevention: A Systematic Review and Meta-analysis},
journal = {Aesthetic Surgery Journal},
year = {2026},
doi = {10.1093/asj/sjag204}
}
EUVIMED